ARVN Stock Analysis: Arvinas | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 450m USD | 12M Return: -32.6% | US04335A1051 | Charts, Fundamentals & Technical Analysis

Protein Degraders, Neurodegenerative Disease, Oncology, Breast Cancer
Total Rating 18
Safety 69
Buy Signal -0.50
Pharmaceuticals
Sub-Industry Rotation: +7.2
Market Cap: 450M
Avg Turnover: 6.39M
Risk 3d forecast
Volatility60.6%
VaR 5th Pctl10.1%
VaR vs Median0.74%
Reward TTM
Sharpe Ratio-0.50
Rel. Str. IBD5.2
Rel. Str. Peer Group13 pctl
Character TTM
Beta1.608
Beta Downside2.573
Hurst Exponent0.492
Choppyness60.9%
Drawdowns 3y
Max DD88.40%
CAGR/Max DD-0.36
CAGR/Mean DD-0.49
EPS (Earnings per Share) EPS (Earnings per Share) of ARVN over the last years for every Quarter: "2021-09": -0.94, "2021-12": -1, "2022-03": -1.2, "2022-06": -1.32, "2022-09": -1.24, "2022-12": -1.56, "2023-03": -1.54, "2023-06": -1.25, "2023-09": -1.18, "2023-12": -2.53, "2024-03": -0.97, "2024-06": -0.49, "2024-09": -0.68, "2024-12": -0.63, "2025-03": 1.14, "2025-06": -0.84, "2025-09": -0.48, "2025-12": -1.1, "2026-03": -0.9, "2026-06": 2.58, "2026-09": -0.82,
Last SUE: -0.02
Qual. Beats: 0
Revenue Revenue of ARVN over the last years for every Quarter: 2021-09: 9.3, 2021-12: 26.3, 2022-03: 26.5, 2022-06: 33.8, 2022-09: 33.2, 2022-12: 38, 2023-03: 32.5, 2023-06: 54.5, 2023-09: 34.6, 2023-12: -43.1, 2024-03: 25.3, 2024-06: 76.5, 2024-09: 102.4, 2024-12: 59.2, 2025-03: 188.8, 2025-06: 22.4, 2025-09: 41.9, 2025-12: 9.5, 2026-03: 15.6, 2026-06: 249.7, 2026-09: 0.5,
Rev. CAGR: 51.58%
Rev. Trend: 56.7%
Last SUE: -0.21
Qual. Beats: 0

Warnings

High Debt While Negative Cash Flow
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 8.1 years of data, until 10/2026

Jan -0.0% 0
Feb +0.2% 0
Mar -13.9% 38
Apr +2.2% 0
May -8.5% 18
Jun +1.1% 5
Jul +5.5% 38
Aug -2.3% 0
Sep -5.0% 18
Oct +5.9% 0
Nov +12.7% 18
Dec +0.8% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: ARVN Arvinas

Arvinas is a clinical-stage biotechnology company that develops therapies based on targeted protein degradation, using its proprietary PROTAC (proteolysis targeting chimera) platform to eliminate disease-causing proteins rather than merely inhibit them. Unlike traditional small-molecule inhibitors that block protein activity temporarily, PROTACs recruit the cells natural ubiquitin-proteasome system to degrade target proteins, a modality that has attracted significant partnership interest from large pharmaceutical companies.

The companys pipeline spans neurodegenerative diseases, oncology, and rare disorders, with notable programs including ARV-102 targeting LRRK2 for Parkinsons disease and progressive supranuclear palsy, ARV-806 targeting KRAS G12D-mutant cancers, and vepdegestrant, an estrogen receptor degrader for ER+/HER2- breast cancer. Arvinas also has collaborations with major pharmaceutical partners including Pfizer, Genentech/Roche, and Bayer, which provide development funding and validation of its platform. Founded in 2013 and headquartered in New Haven, Connecticut, the company went public in 2018 and operates as a small-cap clinical biotech, meaning it is not yet generating commercial product revenue and relies on partnerships and capital markets to fund its research and development activities.

Headlines to Watch Out For
  • Vepdegestrant Phase 3 breast cancer data with Pfizer
  • ARV-102 Parkinsons and ARV-806 KRAS trial readouts
  • Cash burn and dilution risk as trials advance
Piotroski VR-10 (Strict) 1.5
Net Income: -9.50m TTM > 0 and > 6% of Revenue
FCF/TA: -0.26 > 0.02 and ΔFCF/TA 12.72 > 1.0
NWC/Revenue: 188.0% < 20% (prev 218.2%; Δ -30.17% < -1%)
CFO/TA -0.26 > 3% & CFO -158.3m > Net Income -9.50m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.39 > 1.5 & < 3
Outstanding Shares: last quarter (65.4m) vs 12m ago -10.29% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 37.93% > 50% (prev 36.99%; Δ 0.94% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 2.77
A: 0.85 (Total Current Assets 587.6m - Total Current Liabilities 70.0m) / Total Assets 607.5m
B: -2.56 (Retained Earnings -1.55b / Total Assets 607.5m)
C: -0.03 (EBIT TTM -25.2m / Avg Total Assets 725.9m)
D: 5.48 (Book Value of Equity 513.8m / Total Liabilities 93.7m)
Altman-Z'' = 2.77 = A
Beneish M -2.50
DSRI: 0.22 (Receivables 5.30m/26.8m, Revenue 275.3m/312.3m)
GMI: 1.02 (GM 97.89% / 95.86%)
AQI: 3.03 (AQ_t 0.01 / AQ_t-1 0.00)
SGI: 0.88 (Revenue 275.3m / 312.3m)
TATA: 0.24 (NI -9.50m - CFO -158.3m) / TA 607.5m)
Beneish M = -2.50 (Cap -4..+1) = A
What is the price of ARVN shares?

As of November 15, 2026, the stock is trading at USD 6.82 with a total of 879,353 shares traded. Over the past week, the price has changed by +6.40%, over one month by -0.29%, over three months by -24.31% and over the past year by -32.61%.

Current recommended Stop Loss: 6.20 (which is 9.1% or 1.4 ATR below the current price).

Is ARVN a buy, sell or hold?

Arvinas has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold ARVN.

  • StrongBuy: 5
  • Buy: 2
  • Hold: 8
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ARVN price?
Analysts Target Price 14 105.3%
Arvinas (ARVN) - Fundamental Data Overview as of 14 November 2026
Market Cap USD = 449.9m (449.9m USD * 1.0 USD.USD)
P/E Forward = 17.8571
P/S = 1.6342
P/B = 0.8801
Revenue TTM = 275.3m USD
EBIT TTM = -25.2m USD
EBITDA TTM = -20.6m USD
Long Term Debt = 200k USD (from longTermDebt, last quarter)
Short Term Debt = 2.10m USD (from shortTermDebt, last quarter)
Debt = 14.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.20m
Net Debt = -543.6m USD (calculated: Debt 14.8m - CCE 558.4m)
Enterprise Value = 449.9m USD (floored to Market Cap, CCE > MCap+Debt)
 Interest Coverage Ratio = unknown (Ebit TTM -25.2m / Interest Expense TTM 0.0)
 EV/FCF = -2.82x (Enterprise Value 449.9m / FCF TTM -159.8m)
FCF Yield = -35.52% (FCF TTM -159.8m / Enterprise Value 449.9m)
FCF Margin = -58.05% (FCF TTM -159.8m / Revenue TTM 275.3m)
Net Margin = -3.45% (Net Income TTM -9.50m / Revenue TTM 275.3m)
 Gross Margin = unknown ((Revenue TTM 275.3m - Cost of Revenue TTM 11.4m) / Revenue TTM)
 Tobins Q-Ratio = 0.74 (Enterprise Value 449.9m / Total Assets 607.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 14.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -19.9m (EBIT -25.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.39 (Total Current Assets 587.6m / Total Current Liabilities 70.0m)
Debt / Equity = 0.03 (Debt 14.8m / totalStockholderEquity, last quarter 513.8m)
 Debt / EBITDA = 26.39 (negative EBITDA) (Net Debt -543.6m / EBITDA -20.6m)
 Debt / FCF = 3.40 (negative FCF - burning cash) (Net Debt -543.6m / FCF TTM -159.8m)
 Total Stockholder Equity = 474.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.31% (Net Income -9.50m / Total Assets 607.5m)
RoE = -2.00% (Net Income TTM -9.50m / Total Stockholder Equity 474.1m)
RoCE = -5.31% (EBIT -25.2m / Capital Employed (Equity 474.1m + L.T.Debt 200k))
 RoIC = -3.79% (negative operating profit) (NOPAT -19.9m / Invested Capital 525.8m)
 WACC = 10.69% (E(449.9m)/V(464.7m) * Re(11.04%) + D(14.8m)/V(464.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -78.98 | Cagr: -4.12%
 [DCF] Fair Price = unknown (Cash Flow -159.8m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: 56.70 | Revenue CAGR: 51.58% | SUE: -0.21 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.79 | Chg30d=+12.10% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=0.16 | Chg30d=+216.13% | Revisions=+36% | GrowthEPS=+114.0% | GrowthRev=+5.7%
EPS next Year (2027-12-31): EPS=-3.18 | Chg30d=+1.71% | Revisions=+0% | GrowthEPS=-2096.1% | GrowthRev=-82.8%
[Analyst] Revisions Ratio: +14% (up=11, down=8)